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Recently, several new urinary gonadotrophin preparations 
have been developed, containing less luteinizing hormone 
(LH) activity than human menopausal gonadotrophin. 
Normegon is a gonadotrophin preparation with a follicle 
stimulating hormone (FSH)/LH ratio of 3:1; Follegon and 
Metrodin-HP are purified FSH preparations. The aim of 
the present randomized study was to compare pharmaco­
dynamics, -kinetics and local tolerance of these prepara­
tions after repeated s.c. administration. Thirty-six healthy 
female subjects were treated with Lyndiol contraceptive 
pills for 5 weeks to suppress endogenous gonadotrophin 
concentrations. After 3 weeks of Lyndiol treatment, 150 IU 
of Normegon, Follegon or Metrodin HP were administered 
once daily, s.c. for 7 days. Blood samples were collected 
once daily during the fourth and fifth weeks of the study 
and assayed for FSH and oestradiol. After the last 
gonadotrophin injection, blood samples were collected more 
frequently to determine pharmacokinetic parameters of 
FSH. During the fourth and fifth study weeks, daily 
ultrasound measurements of follicular growth were per­
formed. Endogenous FSH and LH values were extremely 
suppressed during Lyndiol treatment. Serum FSH values 
showed similar patterns in the three groups. The maximum 
FSH concentration was reached 9-11 h post-injection, the 
terminal half-life was 43-47 h. The preparations were 
bioequivalent with respect to FSH immunoreactivity. The 
number of follicles tended to be larger after Normegon 
than after Follegon and Metrodin HP treatment, though 
this was not statistically significant. Serum oestradiol con­
centrations were significantly higher after Normegon treat­
ment. In general, s.c injections were well tolerated. In 
conclusion, the three preparations were bioequivalent with 
respect to FSH immunoreactivity. Nevertheless, the bio­
logical activity of Normegon tended to be higher than that of 
Follegon and Metrodin HP in Lyndiol-suppressed women. 
Key words: FSH/gonadotrophin/pharmacodynamics/pharmaco­
kinetic s/sub cutaneou s
Introduction
Human menopausal gonadotrophin (HMG) has been used on 
a large scale for more than 30 years. This urinary preparation 
contains equal amounts of follicle stimulating hormone (FSH) 
and luteinizing hormone (LH) activity. If the LH bioactivity 
is too low after extraction from urine, human chorionic 
gonadotrophin (HCG) is added to the preparation to increase 
the amount of LH bioactivity. Administration of exogenous 
LH does not appeal* to be necessary for adequate ovarian 
stimulation in normogonadotrophic women, even during 
pituitary suppression by a gonadotrophin-releasing hormone 
(GnRH) agonist (Devroey et a l , 1994). In gonadotrophin- 
deficient women, however, although multiple follicular growth 
is observed after treatment with pure (recombinant) FSH, serum 
17(i-oestradiol concentrations remain very low (Schoot et c il, 
1994; Balasch et al., 1995). So a minor amount of LH is 
required for adequate steroid synthesis by the ovarian follicles. 
Lately several new urinary preparations have been developed, 
containing less LH bioactivity than HMG. Normegon is 
produced in the same way as HMG, but no HCG is added to 
this preparation. One ampoule contains 75 IU FSH and 25 IU 
LH in-vivo bioactivity. Follegon is a purified FSH preparation, 
containing 75 IU FSH and virtually no LH activity, Metrodin 
HP is a highly purified FSH preparation, from which non-FSH 
proteins are largely removed. The primary objective of the 
present study was to compare the effects of Normegon, 
Follegon and Metrodin HP on follicular growth and oestradiol 
production.
Gonadotrophin preparations are usually administered i.m. 
These preparations can also be administered s.c., in particular 
highly purified preparations such as MeU*odin HP or recom­
binant human FSH (Howies et a l , 1994; Recombinant FSH 
Study Group, 1995). S.c. injections are preferable to i.m. 
injections, because they are more suitable for self-administra­
tion by the patient. Therefore, in the present suidy the three 
gonadotrophin preparations were administered s.c.. A second 
objective of the study was to investigate the 7 day multiple- 
dose pharmacokinetics of Normegon, Follegon and Metrodin 
HP and the local tolerance of the s.c. route. The study subjects 
used Lyndiol contraceptive pills to suppress endogenous 
gonadotrophin concentrations, enabling investigation of both 
pharmacodynamic and pharmacokinetic parameters of exogen­
ous FSH preparations.
Materials and methods
Subjects
Thirty-six healthy female volunteers participated in the study. Inclu­
sion criteria were: age between 18 and 39 years, use of oral
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contraceptives for at least 3 months (not originally prescribed for 
menstrual irregularities), body weight between 50 and 75 kg and 
between 80 and 130% of the ideal body weight (according to the 
Metropolitan Life Insurance Company tables). The most important 
exclusion criteria were: endocrine abnormalities such as hyper- 
prolactinaemia, polycystic ovary syndrome and absence of ovarian 
function, hypertension, chronic cardiovascular, hepatic, renal or pul­
monary disease, abuse of alcohol or drugs, protein allergy. Prior to the 
start of the study, all subjects underwent a physical and gynaecological 
examination including a cervical smear and transvaginal ultrasono­
graphy. Blood samples were obtained to determine routine haemato­
logy and blood biochemistry.
All subjects gave their written informed consent. The study was 
approved by an independent ethical committee (STEG).
Study protocol
The subjects were divided in a randomized way into three study 
groups of 12 subjects each. After a pill-free period of 7 days, all 
subjects were treated with Lyndiol contraceptive pills (NV 
Organon, Oss, The Netherlands; 50 jug ethinyl oestradiol and 2.5 mg 
lynestrenol per tablet) during 5 weeks to suppress endogenous 
gonadotrophin activity. The first day of Lyndiol treatment was called 
study day 1. After 3 weeks of Lyndiol pretreatment, from day 22 
onwards, 150 IU of either Normegon (NV Organon), Follegon 
(NV Organon) or Metrodin HP (Laboratoires Serono SA, Geneva, 
Switzerland) were injected once daily s.c. in the abdominal wall. 
Gonadotrophin treatment was given for 7 days. Lyndiol treatment 
was continued for 1 week after the last gonadotrophin injection.
Gonadotrophin injections were given at a fixed time point. The 
injection site of the previous day was inspected and local reactions 
(redness, itching, swelling, pain, bruising) were scored as either 
none, mild, moderate, or severe. Transvaginal ultrasonography was 
performed once daily from study day 20 until day 35 to measure all 
visible follicles. Blood sampling was performed once daily from day 
20 until day 35 between 7.30 and 9.00 a.m., just prior to the 
gonadotrophin injection. On day 28, the seventh day of gonadotrophin 
administration, a blood sample was obtained prior to the last injection 
and subsequently 1, 2, 4, 6, 8, 10, 12, 16, 24, 30, 36 and 48 h after 
the injection. The subjects kept bed rest from 1 h before until 12 h 
after the last injection. Heavy exercise and alcohol consumption of 
more than one glass per day were not allowed during die week of 
gonadotrophin treatment until 3 days thereafter.
Gonadotrophin preparations
One batch of each preparation was used for the study. The FSH 
immunoreactivity in five ampoules from each batch was determined 
by a time-resolved fluoroimmunoassay (Delfia; Pharmacia, Woerden, 
The Netherlands). FSH isohormone profiles of the three batches were 
determined by chromatofocusing according to Matikainen 
et al. (1994).
Assays
Blood samples were allowed to clot for 30 min, then centrifuged for 
15 min at 2000 g. Sera were stored at -20°C until assayed. Serum 
concentrations of FSH and oestradiol were determined in each sample 
by time-resolved fluoroimmunoassays (Delfia; Pharmacia). Serum LH 
concentrations were determined on days 21, 24, 28 (before injection) 
and 32, using a time-resolved fluoroimmunoassay (Delfia; Pharmacia). 
These two-site assays employ a (3-directed capturing monoclonal 
antibody (MCA) and an a-directed europium labelled detection MCA. 
The assays were performed as described by the manufacturer using thè 
Delfia instrumentation software and MultiCalc software (Pharmacia). 
FSH and LH immunoreactivity was expressed in terms of the Second
International Reference Preparation (IRP) of pituitary FSH (code no. 
78/549) and the Second International Standard (IS) for pituitary LH 
(code no. 80/552). The intra- and interassay coefficients of variation 
(CV) were <7.5% (range 4.3-7.5) and <6.4% (range 5.1-6.4) for 
FSH and <5.4% (range 2.0-5.4) and <10.5% (range 8.6-10.5) for 
LH, respectively. The intra- and interassay coefficients of variation 
of the oestradiol assay were <7.7% (range 3.3-7.7) and <10,7% 
(range 4.4-10.7), respectively.
Data analysis
**
Several pharmacokinetic parameters .were calculated: the concentra­
tion as measured just before each dosing and 24 h after the last 
dosing, the peak concentration (Cmax) and the time of its occurrence 
(tjnax)' The elimination half-life (t1/2) was estimated using log-linear 
regression on the terminal data points of the concentration-time 
curve, the area under the curve (AUC0-24) over one dosing interval 
was calculated by means of the linear trapezoidal rule. The clearance 
was calculated by dividing the administered immunoreactive dose by 
the AUCo-24» and was expressed in relation to the body weight (Cl/kg).
The groups were compared with respect to age, height, weight and 
extent of suppression by a one-way analysis of variance (ANOVA) 
and the Kruskal-Wallis test. The Kruskai-Wallis test was used to 
compare the groups with respect to numbers of follicles and serum 
oestradiol concentrations. A repeated measures ANOVA was per­
formed on the log-transformed values of the pre-dose values and the 
24 h value after the last injection in order to check whether steady 
state had been reached. The predose concentration was corrected for 
differences in ampoule contents.
A one-way ANOVA was performed on the log-transformed values 
of the parameters Craax, tj/2, AUCq_24 and Cl/kg. Cmax and AUC0^ 4 
were corrected for differences in ampoule contents. Differences in 
tmax were tested using the Kruskal-Wallis test. For the parameters 
Cmax, ti/2* AUC0-24 and Cl/kg, a 90% confidence interval (Cl) for 
the true ratio ‘test/reference’ was derived from the ANOVA. The 
Metrodin HP treatment was designated as ‘reference’, Normegon and 
Follegon as ‘test\ In the case of comparison between Normegon and 
Follegon, Normegon was designated as ‘reference*. Two preparations 
were considered bioequivalent with respect to a certain parameter 
when the 90% Cl of the ratio was fully contained within a range of
0.80-1.25.
Results
The three groups appeared to be comparable with respect to 
age (mean ± SD: 23 ± 4.7, 22 ± 2.2, 24 ± 4.1 years 
in the Normegon, Follegon and Metrodin HP group, respect­
ively), height (1.69 ± 2.9, 1.72 ±  4.2, 1.71 ± 6.8 m) and 
body weight (62 ± 5.8, 65 ± 3.7, 63 ±  7.0 kg). The mean 
(± SD) FSH immunoreactivity was 36.6 ±  0.7, 36.6 ± 0.9 
and 40,6 ± 0.9 IU in the Normegon, Follegon and Metrodin 
HP ampoules, respectively. The isohormone profiles of the 
three batches appeared to be very similar (Figure 1).
In all groups serum LH concentrations were extremely 
low, <0.4 IU/1, during the entire study period. Serum FSH 
concentrations were also extremely suppressed after 3 weeks 
of Lyndiol treatment (Figure 2). Mean FSH concentrations 
before gonadotrophin treatment were <1.0 IU/1. During 
gonadotrophin treatment FSH concentrations increased until 
after 4 days a plateau phase was reached. FSH values were 
slightly higher in the Metrodin HP group than in the other 
two groups. However, when the serum FSH values were
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follicles with a diameter > 8  mm on each study day. Median 
values of the number of follicles with a diameter of 8 or 9 
mm, 10 or 11 mm and 12 or 13 mm are shown in Figure 3. 
The largest number of follicles was seen on the second post­
treatment day, study day 30. On day 30, the number of follicles 
with a diameter of 8 or 9 mm was 4.5 (1-15), 4 (0-10) and
1.5 (0-16), in the Normegon, Follegon and Metrodin HP 
group, respectively (median and range). The number of follicles 
with a diameter of 10 or 11 mm was 2.5 (0-7), 1 (0-7) and 
0.5 (0-19); the number of follicles with a diameter of 12 or
13 mm was 0.5 (0-5), 0 (0-1) and 0 (0-19), in the Normegon, 
Follegon and Metrodin HP group. The number of follicles 
tended to be higher in the Normegon than in the Follegon and 
Metrodin HP group, and follicles tended to be larger in the 
Normegon group, but the differences were not statistically 
significant probably because of the large interindividual 
variation. Serum oestradiol concentrations were low during 
the entire study period. Only in the Normegon group was a 
small increase in serum oestradiol concentrations seen after 
several days of gonadotrophin treatment, and a median peak 
value of 127 pmol/1 (range 56-420) was seen on the first post­
treatment day (day 29), The median oestradiol concentration 
on day 29 was 67 pmol/1 (range 50-122) in the Follegon 
group, 54 pmol/1 (range 50-194) in the Metrodin HP group. 
Serum oestradiol concentrations were significantly higher in 
the Normegon group than in the other two groups (0.01 <  P 
<  0.05 on days 25 and 26; P  <  0.01 on days 27, 28 and 29).
Generally, the s.c. injections were well tolerated. The item 
‘redness’ was scored as ‘severe’ by two subjects in the 
Normegon group on four and two treatment days, respectively, 
the item ‘pain1 was scored as ‘severe’ by these two subjects 
on three treatment days. The item ‘bruising’ was scored once 
by one of these subjects as ‘severe’. The items ‘itching’ and 
‘swelling* were never scored as ‘severe’. In the Follegon group 
none of tire subjects scored any of the items as ‘severe’, on a 
few occasions ‘moderate’ was scored for redness, swelling or 
pain. In the Metrodin HP group none of the items was scored 
as ‘moderate’ or ‘severe’.
. .  4
--  3.5
-- 3
1-3 10 15
I iM ytl.I ■ ■[
20 25 30
2.5
35
Fraction no.
40 45 50 55 60
Discussion
Endogenous serum FSH and LH concentrations after 3 
weeks of Lyndiol treatment appeared to be suppressed more 
severely than after GnRH agonist treatment (Devroey et a l ,  
1994), and to resemble the gonadotrophin concentrations of 
gonadotrophin-deficient women (Schoot et a l , 1994). Serum 
LH values remained at very low concentrations during the 
entire study, so endogenous gonadotrophins were adequately 
suppressed during the gonadotrophin treatment. Administration 
of exogenous LH in the Normegon group did not result in an 
increase of serum LH values, probably because of the short 
corrected for the differences in ampoule contents, as determined half-life of LH. Serum FSH concentrations were slightly 
by immunoassay, the FSH curves of the three groups were higher after Metrodin HP than after Normegon and Follegon 
almost identical. Pharmacokinetic parameters did not show administration. However, the amount of immunoreactive FSH 
significant differences between the groups (Table I). The in the Metrodin HP ampoules was somewhat higher than in 
preparations appeared to be bioequivalent with respect to FSH the other ampoules. After correction of immunoreactive serum 
immunoreactivity. FSH values for the differences in content of the ampoules,
Table II depicts median values of the total number of no differences could be detected any more, and the three
Figure 1. Follicle stimulating hormone (FSH) isohormone profiles 
of the batches of Normegon (lower panel), Follegon (middle 
panel) and Metrodin HP (upper panel) used for the study.
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Figure 2. Mean (SD) serum FSH concentrations before (days 20-21), during (days 22-28) and after (days 29-35) 7 day s.c. administration 
of 150IU Normegon (solid diamonds), Follegon (hatched squares) or Metrodin HP (stippled triangles); without (A) and with (B) correction 
for differences in ampoule contents.
Table I. Pharmacokinetic parameters of follicle stimulating hormone (FSH)
Normegon Follegon Metrodin HP
*max (h)
c ma* am 
n-cmax am
AUCq-24 (IU.h/1) 
n-AUCo_24 (IU.h/1) 
Cl/kg (1/h)
*1/2 (h)
8.83 ± 2.89 
8.98 ± 1.57 
0.245 ± 0.043 
197 ± 34.9 
5.39 ± 0.95 
0.0031 ± 0.0006 
43.48 ± 3.65
9.83 ± 3.95 
9.53 ± 1.85 
0.260 ± 0.051 
204 ± 37.6 
5.59 ± 1.03 
0.0028 ± 0.0005 
44.01 ± 2.98
11.17 ± 4.13 
10.92 ± 2.10 
0.269 ± 0.052 
234 ± 41.4 
5.77 ± 1.02 
0.0028 ± 0.0004 
46.63 ± 4.71 
«
Values are mean ± SD. n-Cmax and n-AUCo_24 are Cmax and AUCq_24 
normalized for FSH ampoule content (Cmax and AUCo_24 divided by 36.6 or
40.6).
AUC: area under the curve; Cmax, tmax: peak concentration and its time;
Cl: ^ clearance.
preparations appeared to be bioequivalent with respect to 
serum FSH immunoreactivity. In addition, Out et a l  (1996) 
have previously demonstrated bioequivalence between Folle-
gon and Metrodin. The elimination half-life of FSH of ~45 h 
was rather long in comparison with that found by Le Cotonnec 
et al  (1994a,b). They calculated an elimination half-life of 37 
h after a single s.c. administration of recombinant human 
FSH (Gonal-F), and a half-life of 24 h after multiple s.c. 
administration. The difference may be caused by variation in 
FSH isohormone profiles of the applied preparations. If more 
acidic isohormones are present, the half-life will be longer 
(Wide and Hobson, 1986). Another explanation may be that 
the subjects in the study by Le Cotonnec et al. were treated 
with a GnRH agonist to suppress endogenous gonadotrophins. 
As was mentioned earlier, the endogenous gonadotrophins 
were less profoundly suppressed during GnRH agonist than 
during Lyndiol treatment. Exogenous FSH can be measured 
for a longer time period if endogenous FSH is more adequately 
suppressed. Since the half-life was estimated from the terminal 
part of the disappearance curve, the estimated value will be 
influenced by the degree of pituitary suppression. In a previous
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Table II. Numbers of follicles >8 mm before (days 20-21), during (days 
22-28) and after (days 29-35) 7 day s.c. administration of 150 IU 
Normegon, Follegon or Metrodin HP
Study day Normegon Follegon Metrodin HP
20 0 (0-0) 0 (0-0) 0 (0-0)
21 0 (0-0) 0 (0-0) 0 (0-0)
22 0 (0-0) 0 (0-0) 0 (0-0)
23 0(0-0) 0 (0-0) 0 (0-0)
24 0 (0-0) 0 (0-0) 0 (0-0)
25 0 (0-6) 0 (0-0) 0 (0-1)
26 0 (0-6) 0 (0-4) 0.5 (0-10)
27 2.5 (0-7) 0.5 (0-4) 1 (0-25)
28 5.5 (0-12) 2 (0-14) 2 (0-33)
29 6.5 (3-17) 3.5 (0-16) 3.5 (0-55)
30 7.5 (1-17) 5 (0-16) 2 (0-62)
31 5 (0-18) 3 (0-20) 1.5 (0-37)
32 6(0-15) 2.5 (0-18) 2.5 (0-45)
33 6 (0-15) 3 (0-13) 1.5 (0-45)
34 3 (0-13) 0 (0-11) 0 (0-42)
35 2 (0-11) 0 (0-5) 0.5 (0-34)
Values are median (range).
N follicles
SO 21 22 23 24 25 26 27 20 29 30 31 32 33 34 35
Day
N follicles
8
0
B
20 21 22 23 24 25 26 27 20 29 30 31 32 33 34 35
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Figure 3. Median number of follicles with a diameter of 8 or 9 
mm, 10 or 11 mm and 12 or 13 mm before (days 20-21), during 
(days 22-28) and after (days 29-35) 7 day s.c. administration of 
150 IU Normegon (A), Follegon (B) or Metrodin HP (C).
study, pharmacokinetic parameters of Follegon and Metrodin 
were determined after a single i.m. injection in women treated 
with Lyndiol (Out et al., 1996). The elimination half-lives 
calculated in this study (Follegon 38 h, Metrodin 44 h) were 
comparable to our results after s.c. administration.
Serum oestradiol concentrations were significantly higher 
in the Normegon group than in the other groups. The higher 
oestradiol concentrations may be correlated with the larger 
number of follicles in the Normegon group. Another explana­
tion for the increased oestradiol concentrations may be the 
higher amount of LH in Normegon. Previous studies in 
in-vitro fertilization (IVF) cycles showed that even pure 
(recombinant) FSH preparations could stimulate oestrogen 
production (Devroey et al., 1994). However, in these cycles 
endogenous gonadotrophins were suppressed by GnRH 
agonists. In the present study, endogenous LH values were 
much lower, and resembled those of the gonadotrophin- 
deficient women in the studies by Couzinet et al. (1988), 
Schoot et a l  (1994) and Balasch et al. (1995). In these women, 
serum oestradiol concentrations hardly increased during puri­
fied urinary FSH and recombinant FSH treatment, respectively. 
Possibly, in our study group, the minor amount of LH in 
Follegon and Metrodin HP was insufficient to stimulate 
oestrogen production.
Although the three preparations were bioequivalent with 
respect to FSH immunoreactivity, the number of follicles and 
the follicular diameter tended to be larger in the Normegon 
group. Apparently, although the immunological FSH activity 
was similar in the three groups, the biological effect was 
different. Two possible explanations can be given for the 
observed differences. A first explanation may be the presence 
of different amounts of urinary components other than FSH. 
The production process of the preparations differs in some 
way Normegon is purified from female urine. To obtain a 
purified FSH preparation (Follegon), a polyclonal antibody to 
LH/HCG is used, which removes most of the LH activity, 
Metrodin HP is produced from the HMG bulk material 
using a monoclonal antibody to FSH and a number of high 
performance liquid chromatography steps, thus removing most 
of the contaminating urinary proteins. If these urinary proteins 
are capable of stimulating follicular growth, differences in 
biological activity between the preparations might occur. 
However, Normegon and Follegon are substantially the same 
products, apart from the removed LH activity, which makes 
this explanation less likely A second explanation may be that 
the higher amount of exogenous LH in Normegon exerts a 
stimulatory effect on follicular growth. It is generally accepted 
that FSH, not LH, stimulates follicular growth, However, 
LH stimulates androgen production, and these androgens are 
converted into oestrogens. Oestrogens exert autocrine and 
paracrine effects within the ovary For instance, oestrogens 
stimulate the proliferative activity of granulosa and theca cells 
and enhance the responsiveness of granulosa cells to FSH 
(Rao et a i , 1978; Richards, 1980). Thus, oestradiol may 
enhance the stimulation of follicular growth by FSH. 
Furthermore, LH might stimulate the production of growth 
factors within the ovary, which exert paracrine effects and 
may also play a role in the process of follicular growth.
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Loumaye et a l  (1995) described preliminary results of a study 
in gonadotrophin-deficient women, treated with recombinant 
FSH (Gonal-F, 150 IU daily) and different amounts of recom­
binant LH (0, 25, 75 and 225 IU daily). Interestingly, they 
observed that co-administration of LH led to a dose-related
4
enhancement of the number of follicles and serum oestradiol 
concentrations. They concluded from their results that 75 IU 
LH per day was an effective dose for the majority of their 
patients. The results of this study would support our theory 
that, at least in hypogonadotrophic women, more exogenous 
LH might stimulate follicular growth. The results of a study 
by Fleming et al. (1996) also support this theory. They 
demonstrated that infertile women with low follicular phase 
s p i n  LH concentrations (<1 IU/1), who were treated with 
Metrodin HP during 7 days, had significantly smaller follicles 
and lower serum oestradiol concentrations than patients with 
serum LH values 2* 1 IU/1 who were treated with HMG, Results 
from patients who had serum LH values >1  IU/1 and were 
treated with Metrodin HP were intermediate.
In general, the s.c. gonadotrophin injections were well 
tolerated. In the Normegon group, more local skin reactions 
were observed than in the other groups, although hardly any 
severe reactions were seen. In clinical practice, especially 
Follegon and Metrodin HP are very suitable for s.c. adminis­
tration.
In conclusion, treating female volunteers with Lyndiol 
contraceptive pills resulted in extremely suppressed endogen­
ous gonadotrophin concentrations. Normegon, Follegon and 
Metrodin HP were bioequivalent with respect to FSH immuno- 
reactivity. Despite this bioequivalence, the biological effect of 
Normegon tended to be greater in our study group of Lyndiol- 
treated subjects, possibly due to the higher amount of LH in 
this preparation. This observation will not have consequences 
for routine IVF practice, since endogenous LH concentrations 
of IVF patients are higher than in the present study group, 
even during GnRH agonist treatment, and the amount of 
exogenous LH appears to be not very relevant (Bentick et a l , 
1988; Daya et a l , 1995). In women with extremely low 
endogenous LH concentrations, however, the amount of 
exogenous LH will probably influence the effect of gonadotro­
phin treatment.
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